April – June 2015
- Net sales was MSEK 3,441 (3,357). Organic sales growth was 3.5% (4.1) and total sales growth was 2.5% (6.9)
- Operating result (EBITDA) was MSEK 237 (223)1 with an operating margin of 6.9% (6.7)1. EBITDA increased by 6.3% on an adjusted basis
- Operating result (EBITA) was MSEK 136 (115)1 with an operating margin of 4.0% (3.5)1. EBITA increased by 18.3% on an adjusted basis
- Earnings per share SEK -0.25 (0.50)2 and adjusted earnings per share SEK 0.47 (0.28)2
January – June 2015
- Net sales was MSEK 6,919 (6,728). Organic sales growth was 3.2% (4.4) and total sales growth was 2.8% (6.7)
- Operating result (EBITDA) was MSEK 528 (495)1 with an operating margin of 7.6% (7.4)1. EBITDA increased by 6.7% on an adjusted basis
- Operating result (EBITA) was MSEK 327 (284)1 with an operating margin of 4.7% (4.2)1. EBITA increased by 15.1% on an adjusted basis
- Earnings per share SEK 0.33 (0.86)2 and adjusted earnings per share SEK 1.22 (0.93)2
1 For reported numbers for 2014 refer to page 4. Refer to page 27 for definitions of EBITDA and EBITA.
2 Earnings per share and adjusted earnings per share before and after dilution. Refer to note 2 for calculations of earnings per share.
“Our medical strategy continues to deliver stable improvements in sales growth and operating results in all segments.”
We have a clear strategy and focus: In continental Europe, Modern Medicine is driving Rapid Recovery with shorter treatment times and a higher proportion of outpatient treat-ments. In the Nordics, Modern Management will increase the direct patient time for medical staff thus driving higher productivity through empowered people.
In financial terms this translates for the Group into 3.2% organic sales growth in the first six months (3.5% in the quarter) and an improvement in adjusted operating result (EBITA) of 15.1% (18.3% in the quarter).
In the Nordics the focus is on more patient time for doctors and nurses through less administrative duties. Several projects will be implemented during 2015 to speed up this development.
Organic sales growth was for the first six months 5.1% (4.8% in the quarter) and adjusted operating result (EBITA) was up 21.1% (17.2% in the quarter). There was good sales growth and positive development of operating results in Capio St Göran’s hospital, Specialist Clinics and Norway. Proximity Care has limited growth and no result improvements and thus has struggled to outperform last year. In order to improve the development in Proximity Care, there is a very strong focus on increasing the time for patients through more doctor visits per day among other actions.
In France the number of patients operated on increased by 2.1%, including 6.6% outpatient growth and a -6.2% inpatient decrease in the first six months. This means that we are successful in Rapid Recovery moving patients from in- to outpatient treatments in line with our strategy. The share of outpatients operated on has increased by 3 p.p. to 67% out of the total number of patients operated on in the first six months compared to last year. We have also seen the average length of stay (AVLOS) continuing to shorten. During the first half of 2015 we have performed in total 3,465 (3,287) hip and knee replacements, of which 226 (34) in day surgery.
With the French Government’s ambition to push for shorter stays and more outpatient treatments, prices have been decreased from March 1, 2015 with a negative effect on prices with -2.5%. The organic sales growth of 1.2% (1.8% in the quarter) includes the effect of the price reduction as well as the effect from a doctors’ strike, opposing new regulation, in January in certain hospitals. Capio France has put a program in place to speed up implementation of Modern Medicine to compensate for this price decrease. The program is not yet fully up to speed. However, considering the lower prices from March and the doctors’ strike effect in January the result development is positive in the first six months.
In Germany the organic sales growth was 1.1% (2.6% in the quarter) and operating result (EBITA) was up with 11.1%, reflecting an improved performance in the general hospitals (mainly the hospital in Dannenberg).
This is the first financial report made public after the listing of Capio on Nasdaq Stockholm on June 30, 2015. Through the listing, Capio gains long term ownership, further increased transparency and access to capital for expansion. A new era starts for Capio with the long term ambition to further contribute to the renewal of European healthcare implementing Modern Medicine and Modern Management.
President and CEO
Presentation of the interim report
Investors, analysts and media are invited to participate in a telephone conference on July 21, 2015 at 9.30 am (CET). President and CEO Thomas Berglund and CFO Olof Bengtsson will present the report and answer questions. The telephone conference will be audio casted live on www.capio.com. To participate in the telephone conference, please register at www.capio.com and dial in five minutes prior to the start of the conference call.
Sweden: + 46 8 566 426 63
UK: + 44 20 342 814 16
US: +1 855 753 22 35
Finland: +358 981710491
France (toll free): 0805980143
Prior to the start of the telephone conference, presentation slides will be available at www.capio.com.
A recorded version of the audio cast will be available at www.capio.com during the afternoon (CET).
For further information
Thomas Berglund, President and CEO
Telephone: +46 733 88 86 00
Olof Bengtsson, CFO
Telephone: +46 761 18 74 69
Henrik Brehmer, SVP Corporate Communications and Public Affairs
Telephone: +46 761 11 34 14
For further information regarding Capio’s IR activities, refer to www.capio.com/investors
Capio AB (publ) discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.00 (CET) on July 21, 2015.